Nimenrix (MenACWY-TT) / Pfizer |
NCT00453986: Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults |
|
|
| Completed | 3 | 1352 | RoW | Meningococcal vaccine GSK134612, Mencevax™ACWY, Fluarix™ | GlaxoSmithKline | Infections, Meningococcal | 11/07 | 05/08 | | |
NCT00496015 / 2006-001481-17: Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A |
|
|
| Completed | 3 | 750 | RoW | Pneumococcal conjugate vaccine GSK1024850A., Infanrix hexa., DTPa-HBV-IPV/Hib, Meningococcal vaccine GSK134612., Mencevax™, Paracetamol. | GlaxoSmithKline | Infections, Streptococcal | 03/08 | 02/09 | | |
| Completed | 3 | 1025 | RoW | Meningococcal vaccine GSK134612, Mencevax™ ACWY | GlaxoSmithKline | Infections, Meningococcal | 04/08 | 09/08 | | |
| Completed | 3 | 611 | Europe | Nimenrix (Meningococcal vaccine 134612), Twinrix | GlaxoSmithKline | Infections, Meningococcal | 04/08 | 04/08 | | |
NCT00508261 / 2006-006680-23: Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine |
|
|
| Completed | 3 | 793 | Europe | Meningococcal vaccine GSK134612, Infanrix™ hexa, Meningitec™ | GlaxoSmithKline | Infections, Meningococcal | 05/08 | 10/08 | | |
NCT00758264: Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration |
|
|
| Completed | 3 | 363 | RoW | Meningococcal vaccine GSK134612, Pneumococcal vaccine GSK1024850A | GlaxoSmithKline | Infections, Meningococcal | 06/09 | 11/09 | | |
| Completed | 3 | 1558 | US | GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), Nimenrix, GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Menhibrix, Infanrix®, ActHIB®, Pediarix® | GlaxoSmithKline | Infections, Meningococcal | 07/09 | 09/09 | | |
NCT01154088: Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds |
|
|
| Completed | 3 | 1170 | RoW | Mencevax ACWY, GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612] | GlaxoSmithKline | Infections, Meningococcal | 12/10 | 12/10 | | |
NCT01235975: Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years |
|
|
| Completed | 3 | 400 | RoW | Meningococcal vaccine GSK 134612, MencevaxACWY TM | GlaxoSmithKline | Infections, Meningococcal | 07/11 | 08/11 | | |
| Completed | 3 | 697 | RoW | Blood Sampling | GlaxoSmithKline | Infections, Meningococcal | 05/13 | 05/13 | | |
NCT01767376 / 2012-002737-11: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age |
|
|
| Completed | 3 | 692 | Europe, RoW | Meningococcal vaccine GSK134612, MenACWY-TT, Nimenrix, Boostrix®, Tdap | GlaxoSmithKline | Infections, Meningococcal | 01/14 | 01/14 | | |
NCT01755689 / 2012-001876-13: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults |
|
|
| Completed | 3 | 1300 | Europe, RoW | Meningococcal vaccine GSK134612, Nimenrix®, Cervarix®, Boostrix® | GlaxoSmithKline | Infections, Meningococcal | 04/14 | 04/14 | | |
NCT01839175 / 2012-005547-24: Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination |
|
|
| Completed | 3 | 350 | Europe | Hexavalent vaccine, Diphtheria, tetanus, pertussis, hepatitis B,, poliomyelitis and Haemophilus influenzae type b conjugate vaccine (adsorbed)., NeisVac-C, Meningococcal group C polysaccharide conjugate vaccine adsorbed, Prevenar 13, Pneumococcal conjugate vaccine (13-valent, adsorbed), RotaTeq, Human-bovine rotavirus reassortants (live) vaccine, Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, M-M-RVAXPRO, Measles, mumps and rubella vaccine (live) | Sanofi Pasteur, a Sanofi Company | Neisseria Meningitidis, Bacterial Infections, Virus Diseases | 07/14 | 02/15 | | |
NCT01777308 / 2012-002575-34: Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination |
|
|
| Completed | 3 | 156 | RoW | Meningococcal conjugate vaccine GSK134612 | GlaxoSmithKline | Infections, Meningococcal | 07/14 | 04/16 | | |
NCT01641042 / 2011-002410-36: Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects |
|
|
| Completed | 3 | 86 | US, RoW | Meningococcal vaccine GSK134612 | GlaxoSmithKline | Infections, Meningococcal | 10/14 | 03/15 | | |